Michael Brown

Michael Brown

Senior Director, Office Services

License # SL3412270

Call Michael
View More View Less

About

Professional Summary

As Director on the Steering Committee of Colliers Global Life Science Practice Group, I bring 42 years of commercial real estate experience and 22 years of experience focusing on life science real estate. My acquired knowledge in life science work has been on both the landlord (Wexford Science & Technology) and the tenant side within the industry.

I have experience with Gene Therapy, Parenteral Fill Finish, Solid Oral Dosage, Biologics, and Medical Device manufacturing facilities, as well as a solid background in Laboratory Research and Development/Pilot scale facilities and controlled environments. Through my work on local, regional and national site selection assignments, I have developed a firm grasp of the rigorous process required to meet the key search criteria of my clients.  

My knowledge of market conditions and influences in the life sciences supports my ability to be creative in structuring the financial details of both lease and purchase transactions. My network of a wide variety of trusted advisors within the industry facilitates a regular flow of information about life science real estate trends, pricing, and comparable data for leasing and sales transactions.

Accomplishments

Sold and  Leased Over 13,000,000 SF of Life Science Facilities 

Education

BA | English
LaSalle University

Memberships & Involvements

BioFlorida

Clients

Cellectis SA, Alexandria Real Estate; ALMAC Clinical Services; Assembly Bio; BioMed Realty Trust; GSK; NEOSE Technologies; Tengion; The Science Center of Philadelphia; University of Miami; VenatorX; Viro Pharma; Washington University;

Services

Skills
$name
Service Lines
Landlord Representation, Tenant Representation
Property Types
Healthcare-Medical
Specializations
Life Sciences Group

My Team

My Team

Featured Research
Mar 24, 2020
SARS-CoV-2 Impact on the Life Sciences Real Estate Sector
Learn the five trends facing the lab real estate sector as we react to a global pandemic in a new Colliers Life Sciences whitepaper report.
Read More
Feb 25, 2020
In-House or Outsource? Considerations for Biotechs at the Drug Manufacturing Crossroads
In house or outsource to a CDMO? Five considerations for pre-clinical and clinical drug development companies facing critical manufacturing decisions, authored by Joseph Fetterman of the Colliers Life Sciences Practice Group.
Read More
Apr 30, 2019
Philadelphia Life Sciences Perspectives | Q2 2019 Research Report
Philadelphia is consistently a top 10 Life Sciences Cluster in the country. Forces are taking shape that will transform Philadelphia’s formerly decentralized market to a more coherent, attractive and competitive market nationally. We cover the exact composition and nature of the Philadelphia Life Sciences real estate market, the local origins and demand of CAR T-cell therapy, real estate dynamics, and more.
Read More
View More
Featured News
Apr 1, 2020
North Florida is predicted to become a Life Sciences Cluster
Continued development around the University of Florida, Alachua County, and the Mayo Clinic in Jacksonville provide a good foundation for North Florida to become a small life sciences cluster, deems Colliers' life sciences commercial real estate expert, Michael J. Brown.
Read More
Mar 19, 2020
Coronavirus as a Catalyst: How COVID-19 Could Impact Life Science CRE
COVID-19 has impacted virtually every industry, and commercial real estate is no exception. For the life science branch of CRE, the coronavirus could serve as a powerful catalyst that brings increased demand to an already-tight market.
Read More
Mar 19, 2019
UCART Manufacturing Facility Site Selection
We structured a lease for Cellectis, a Paris based clinical-stage biopharmaceutical company, to create an 82,000 square foot commercial-scale manufacturing facility named IMPACT (Innovative Manufacturing Plant for Allogeneic Cellular Therapies) in Raleigh, North Carolina, for clinical and commercial production of Cellectis’ leading allogeneic UCART products.
Read More
Mar 14, 2019
Colliers International Concludes 82,985 sf Lease for New UCART Manufacturing Facility
Colliers International Concludes 82,985 sf Lease for New UCART Manufacturing Facility
Read More
View More

How can I help you?

An unexpected error has occurred. Please try again.
You didn't check the "I'm not a robot" checkbox.
Your request has been submitted.
Someone will contact you shortly.